Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| erythrocyte | 13 studies | 72% ± 20% | |
| erythroblast | 6 studies | 63% ± 17% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 3 studies | 46% ± 23% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| spleen | 88% | 362.37 | 211 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 82% | 3594.27 | 758 / 929 | 0% | 0 | 0 / 0 |
| lung | 56% | 66.35 | 322 / 578 | 2% | 0.06 | 27 / 1155 |
| kidney | 39% | 21.70 | 35 / 89 | 12% | 1.47 | 105 / 901 |
| liver | 42% | 31.94 | 96 / 226 | 4% | 0.45 | 15 / 406 |
| thymus | 22% | 9.76 | 143 / 653 | 7% | 0.16 | 41 / 605 |
| lymph node | 0% | 0 | 0 / 0 | 28% | 2.91 | 8 / 29 |
| brain | 13% | 4.05 | 340 / 2642 | 8% | 0.21 | 55 / 705 |
| heart | 19% | 8.04 | 166 / 861 | 0% | 0 | 0 / 0 |
| adipose | 17% | 9.01 | 209 / 1204 | 0% | 0 | 0 / 0 |
| adrenal gland | 4% | 0.88 | 10 / 258 | 12% | 2.25 | 27 / 230 |
| breast | 14% | 4.29 | 63 / 459 | 2% | 0.05 | 17 / 1118 |
| blood vessel | 9% | 3.91 | 125 / 1335 | 0% | 0 | 0 / 0 |
| esophagus | 7% | 2.57 | 97 / 1445 | 2% | 0.03 | 3 / 183 |
| bladder | 5% | 0.76 | 1 / 21 | 3% | 0.08 | 17 / 504 |
| uterus | 4% | 1.32 | 7 / 170 | 2% | 0.07 | 11 / 459 |
| ovary | 4% | 1.88 | 8 / 180 | 2% | 0.02 | 8 / 430 |
| skin | 4% | 0.89 | 66 / 1809 | 2% | 0.07 | 11 / 472 |
| prostate | 4% | 0.78 | 10 / 245 | 1% | 0.03 | 3 / 502 |
| intestine | 3% | 0.83 | 30 / 966 | 1% | 0.04 | 7 / 527 |
| stomach | 2% | 0.44 | 6 / 359 | 2% | 0.03 | 6 / 286 |
| muscle | 3% | 0.91 | 27 / 803 | 0% | 0 | 0 / 0 |
| pancreas | 0% | 0.11 | 1 / 328 | 1% | 0.01 | 2 / 178 |
| eye | 0% | 0 | 0 / 0 | 1% | 0.02 | 1 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006457 | Biological process | protein folding |
| GO_0030218 | Biological process | erythrocyte differentiation |
| GO_0020027 | Biological process | hemoglobin metabolic process |
| GO_0030097 | Biological process | hemopoiesis |
| GO_0050821 | Biological process | protein stabilization |
| GO_0005833 | Cellular component | hemoglobin complex |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0051082 | Molecular function | unfolded protein binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0030492 | Molecular function | hemoglobin binding |
| Gene name | AHSP |
| Protein name | Alpha hemoglobin stabilizing protein Alpha-hemoglobin-stabilizing protein (Erythroid differentiation-related factor) (Erythroid-associated factor) |
| Synonyms | ERAF EDRF |
| Description | FUNCTION: Acts as a chaperone to prevent the harmful aggregation of alpha-hemoglobin during normal erythroid cell development. Specifically protects free alpha-hemoglobin from precipitation. It is predicted to modulate pathological states of alpha-hemoglobin excess such as beta-thalassemia. . |
| Accessions | H3BSK6 ENST00000302312.9 Q9NZD4 ENST00000564707.1 |